Cochlear receives FDA approval for Nucleus Profile Plus Series

The Cochlear Limited (ASX:COH) share price could be on the rise on Monday after announcing FDA approval for its Nucleus Profile Plus Series…

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Cochlear Limited (ASX: COH) share price will be on watch this morning after the manufacturer and distributor of cochlear implantable devices released an update on its Nucleus Profile Plus Series.

What was in the update?

According to the release, Cochlear has now received U.S. Food and Drug Administration (FDA) approval for the Nucleus Profile Plus Series cochlear implant.

In light of this approval, the company advised that it will commence the launch of the products in the United States immediately. This comes hot on the heels of the launch of the product range in Germany in April.

What is the Nucleus Profile Plus Series?

Cochlear's Nucleus Profile Plus Series is the latest range of Nucleus implants that three decades worth of collaborative clinical and technical research work has created.

The latest implant has been designed for routine 1.5 and 3 Tesla magnetic resonance imaging scans without the need to remove the internal magnet.

This essentially means that users of the implant can undergo a scan such as an MRI without needing to remove the internal magnet or to apply a bandage and splint. This wasn't possible with previous implants, making the new implant much more manageable and convenient for its users.

It is also the thinnest implantable hearing solution on the market at just 3.9mm.

What else is Cochlear working on?

Whilst this new range is arguably the highest quality on the market now, management isn't resting on its laurels.

Earlier this year the company revealed its ambitions for a totally implantable cochlear implant technology. Whilst a commercially available product is not expected for years, it remains a long-term development goal for Cochlear.

According to that release, the new technology being studied "includes an implanted microphone, an implanted rechargeable battery, and an implanted sound processor. This means that the patients can choose between using an external sound processor, or taking it off and relying on the implanted microphone and internal sound processor, while still maintaining hearing function."

Ultimately, the aim is "to provide totally implantable cochlear implant technology that will enable people to hear with and without any externally worn components, helping them to have useful hearing 24 hours a day."

Innovation like this is why Cochlear's shares, and those of equally innovative healthcare stars CSL Limited (ASX: CSL) and ResMed Inc. (ASX: RMD), have generated outstanding returns for their shareholders over the last decade.

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Cochlear Ltd. and CSL Ltd. The Motley Fool Australia has recommended Cochlear Ltd. and ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Businessman using a digital tablet with a graphical chart, symbolising the stock market.
Opinions

2 ASX shares I have been buying in 2024!

I’m a believer in the long-term outlook of these stocks.

Read more »

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a massive day for the ASX 200, with a new all-time high recorded.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

This ASX tech stock rocketed 60% in March! Can it keep on delivering?

After soaring in March, the ASX tech stock is now up 169% since this time last year.

Read more »

Broker Notes

Brokers name 3 ASX shares to buy now

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
Share Fallers

Why Burgundy Diamond Mines, Clarity Pharmaceuticals, EML, and Zip are sinking today

These ASX shares are ending the week in the red. But why?

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Mesoblast, Newmont, Pilbara Minerals, and Platinum shares are jumping

These ASX shares are ending the week strongly. But why?

Read more »

a young boy dressed up in a business suit and tie has a cute grin and holds two fingers up.
Opinions

2 of my top ASX 200 shares to consider buying before April

I would happily exchange dollars for these two shares right now.

Read more »

Father in the ocean with his daughters, symbolising passive income.
Dividend Investing

I'd spend $8k on these ASX 200 shares today to target a $6,102 annual passive income

I believe these ASX 200 shares will continue rewarding passive income investors for years to come.

Read more »